LIPO

Lipella Pharmaceuticals Inc. - Common Stock (LIPO)

About Lipella Pharmaceuticals Inc. - Common Stock (LIPO)

Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. It offers LP-08 which consists of Sphingomyelin Phospholipid bilayers separated by aqueous compartments, LP-09, a liposomal formulation of Botulinum toxin, and LP-10, a proprietary liposomal formulation of Tacrolimus, a potent immunosuppressant and anti-inflammatory agent. The company was founded by Jonathan Kaufman and Michael Chancellor on February 15, 2005 and is headquartered in Pittsburgh, PA.

Details

Daily high

$2.44

Daily low

$2.03

Price at open

$2.26

52 Week High

$12.00

52 Week Low

$1.96

Market cap

6.1M

Dividend yield

0.00%

Volume

2.7M

Avg. volume

177,753

P/E ratio

-.50

Lipella Pharmaceuticals Inc. - Common Stock News